At the 12-month follow-up : 87.5% of patients reported significant relief defined as 50% reduction in baseline pain scores Mean VAS pain score dropped from 7.2 at baseline to 2.8 at 12 months KOOS (Knee Injury and Osteoarthritis Outcome Score) improved across all subscales: pain, symptoms, activities of daily living, sport/recreation, and quality of life No serious adverse events were reported across the treatment period The durability of the response at 12 months is particularly notable
Importantly, none of this research involves human dosing protocols, and no research team has established a standardized administration model appropriate for extrapolation outside laboratory settings
The FDA and FTC one-two punch should dent sales, but as the stem cell wild west has proven, that may not stop sales
PLU Laboratories offers this option with our GHK-Cu serum, available at meaningful concentrations to help you bring out the best in your skin and hair routine with minimal time investment
announced on Joe Rogans podcast in February that hes looking to ease Food and Drug Administration regulations tightened in 2023 on the compounding of 14 popular peptides by pharmacies
They fail because the packaging and labeling stage becomes confusing, expensive, or delayed